Glaxo has reported a sharp drop in sales and PBT for 2QFY02. The results declared by the company were more or less expected by the markets. There is an one time charge of Rs 75 m in 2QFY02 on account of expenses of new launches and restructuring expenses in relation with amalgamation of SmithKline Beecham. Though operating margins have dropped at the look of it, after adjusting for one time charges, the operating margins have remained stable.
(Rs m) | 1HFY01 | 1HFY02 | %Change | 2QFY01 | 2QFY02 | %Change |
Sales | 4,700 | 3,927 | -16.5% | 2,867 | 1,983 | -30.8% |
Other Income | 161 | 147 | -8.6% | 81 | 83 | 3.0% |
Expenditure | 4,244 | 3,631 | -14.4% | 2,555 | 1,850 | -27.6% |
Operating Profit (EBDIT) | 456 | 296 | -35.2% | 312 | 133 | -57.4% |
Operating Profit Margin (%) | 9.7% | 7.5% | 10.9% | 6.7% | ||
Interest | 47 | 42 | -9.0% | 26 | 20 | -23.7% |
Depreciation | 77 | 74 | -4.8% | 38 | 36 | -5.8% |
Profit before Tax | 493 | 327 | -33.8% | 329 | 161 | -51.2% |
Extraordinary Income | 155 | 394 | 105 | 394 | ||
Tax | 212 | 193 | -9.0% | 139 | 129 | -7.3% |
Profit after Tax/(Loss) | 436 | 527 | 20.8% | 295 | 425 | 44.1% |
Net profit margin (%) | 9.3% | 13.4% | 10.3% | 21.4% | ||
No. of Shares (eoy) (m) | 60 | 60 | 60 | 60 | ||
Diluted Earnings per share* | 14.6 | 17.6 | 19.7 | 28.4 | ||
P/E (at current price) | 14.4 | 8.9 | ||||
(*- annualised) |
The decline in turnover can largely be attributed to drop in sales of Ceftum, Cobadex, Forte and Betnesol, the key products for the company. The company has identified 30 strategic key brands, which contributes around 75% of the total turnover. The promotion expenses would be restricted to brands that have potential to provide growth momentum. Going forward, the company also plans to have tighter control over its administrative costs. Glaxo has recently launched an anti asthma (Seretide) an anti-allergy drug (Flixonase) and an smoking cessation pill (Zyban).
At the current market price of Rs 253, the stock is trading at a P/e of 12x its expected earnings for FY02. The company is expected to benefit on account of cost savings from amalgamation with SmithKline Pharma.
For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
In this video, I'll you what I think is the real reason behind yesterday's market crash.
This ignored sector could deliver big short-term profits.
More
Equitymaster requests your view! Post a comment on "Glaxo: 1HFY02 PBT drops 34%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!